Assessment of Effect and Safety of Ripasudil (0.4%) in patients of Primary Open Angle Glaucoma / Ocular Hypertension
Loading...
Date
2022-06
Journal Title
Journal ISSN
Volume Title
Publisher
Scholars Publisher
Abstract
Background: The aim is to evaluate the intraocular pressure-lowering efficacy and tolerability of Ripasudil (0.4%) ophthalmic solution in patients of primary open-angle glaucoma/ocular hypertension.Material & Methods:In this prospective, interventional, single-arm, open-label study, 50 patients of POAG/ocular hypertension attending the Outpatient Department of Ophthalmology, Government Medical College, Patiala were included.Results:Mean value of numerical change in IOP at four weeks, at eight weeks, at twelve weeks in IOP were 3.61 � 2.05, 3.98 � 1.47, 4.44 � 1.53 respectively. Among side effects, conjunctival hyperemia, blepharitis, and allergic conjunctivitis were reported among 62%, 10%, and 8% of the subjects at four weeks. Final results after 12 weeks showed that only conjunctival hyperemia was reported as a side effect among 16% of the subjects. Conclusions:Our present study showed significant IOP-lowering effects and safety of ripasudil (0.4%) over 12 weeks in patients with primary open-angle glaucoma/ocular hypertension. For the treatment of glaucoma and OHT, ripasudil is regarded as a possible second-line choice in spite of the high occurrence of conjunctival hyperemia.
Description
Keywords
Ripasudil, IOP, Conjunctival Hyperemia.
Citation
Singh Ishwar, Singh Harsimran, Sidhu Talvir, Chhabra Neha, Raina Rohit. Assessment of Effect and Safety of Ripasudil (0.4%) in patients of Primary Open Angle Glaucoma / Ocular Hypertension. Annals of International Medical and Dental Research. 2022 Jun; 8(3): 1-7